Mitchell de Long
Corporate Officer/Principal at AERIE PHARMACEUTICALS, INC.
Profile
Mitchell A.
de Long is currently working as the Vice President-Chemistry at Aerie Pharmaceuticals, Inc. He previously worked as a Research Scientist at Procter & Gamble Co. Dr. de Long holds a doctorate degree from Stanford University.
Mitchell de Long active positions
| Companies | Position | Start |
|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2004-12-31 |
Former positions of Mitchell de Long
| Companies | Position | End |
|---|---|---|
| PROCTER & GAMBLE COMPANY | Chief Tech/Sci/R&D Officer | - |
Training of Mitchell de Long
| Stanford University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| Private companies | 1 |
|---|---|
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
- Stock Market
- Insiders
- Mitchell de Long